Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f1d5387ba5fb0080279ed4e0a21dabc5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_25054a6274b6d93c229368ec7e4bbf28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c5073a0063d6be9e25c14d2af0a1ee89 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_465ed46a9d0d59448ad32fb5af2d07c7 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-585 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 |
classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-585 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-56 |
filingDate |
2014-06-20^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2017-08-15^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2bf053c26bddb99926c81285ee870cc1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f741f3b3a2a06a1d484ad4a55305a0a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_36fd3fdc974c0d7409a54ea9db475936 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d2539e29b9244bfe0073931019df0204 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e28c9574a28e5b32908a46fd2931621e |
publicationDate |
2017-08-15^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-9730948-B2 |
titleOfInvention |
Pharmaceutical compositions for preventing glucocorticoid-induced skin thinning |
abstract |
The present invention relates to method and pharmaceutical compositions for preventing glucocorticoid-induced corneal or skin thinning. In particular, the present invention relates to a mineralocorticoid receptor antagonist for topical use in a method for preventing or reducing glucocorticoid-induced corneal or skin thinning in a subject in need thereof. The invention also relates to a topical pharmaceutical composition comprising an amount of at least one glucocorticoid and an amount of at least one mineralocorticoid receptor antagonist or inhibitor of MR expression for use in a method for treating an inflammatory skin disease or an inflammatory disease of the cornea or of the anterior segment of the eye in a subject in need thereof. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10350223-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11338010-B2 |
priorityDate |
2013-06-21^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |